Efficacy and Safety of Kushenin combined with Adefovir Dipivoxil in the Treatment of Chronic Hepatitis B: A Systematic Review_Chinese Journal of Evidence-Based Medicine

Authors：

SU Na ^1,2 , WU Bin ² , XU Ting ² ,  TANG Yao ²

1. West China Medical School, Sichuan University, Chengdu 610041, China;2. Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding?author：

TANG Yao, Email: zoya159@163.com

Keywords：

Kushenin; Adefovir Dipivoxil; Chronic Hepatitis B; Systematic review; Meta-analysis; Randomized controlled trial

DOI：

10.7507/1672-2531.20100567

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To review the efficacy and safety of Kushenin combined with Adefovir Dipivoxil for Chronic Hepatitis B (CHB).
Method 　Randomized controlled trails of Kushenin combined with Adefovir Dipivoxil for CHB were gathered from PubMed, CBMdisc (1978 to 2009), and CSJD (1989 to 2009), while other relative researches were searched manually; every research was evaluated, and then analyzed with RevMan 5.0.0 software.
Result 　Ten randomized controlled trials were included; among total 855 patients, 436 were in trial group and the other 419 were in control group. As the Meta-analysis showed, the therapeutic effect of kushenin combined with Adefovir Dipivoxil was better than that of Adefovir Dipivoxil in aspects of improving the negative rate of serum ALT (RR=1.28, 95%CI 1.17 to 1.40), the negative rate of serum HBV-DNA (RR=1.27, 95%CI 1.13 to 1.42), the negative rate of serum HBeAg (RR=1.80, 95%CI 1.32 to 2.44), and the conversion rate of HBeAg and anti-HBe (RR2.06, 95%CI 1.43 to 2.95).
Conclusion 　Kushenin combined with Adefovir Dipivoxil in treating CHB can improve the conversion rate of HBeAg and anti-HBe and further take better therapeutic effect.

Citation： SU Na,WU Bin,XU Ting,TANG Yao. Efficacy and Safety of Kushenin combined with Adefovir Dipivoxil in the Treatment of Chronic Hepatitis B: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2010, 10(10): 1182-1187. doi: 10.7507/1672-2531.20100567 Copy

1.	Liaw Y F, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18(3): 239-245.
2.	Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to Lamivudine. Hepatolopy, 1998, 27(6): 6701.
3.	楊詩杰. 苦參素聯合拉米夫定對慢性乙型肝炎血清HBsAg影響的Meta 分析. 實用醫學雜志, 2008, 24(13): 2220-2223.
4.	中華醫學會傳染病與寄生蟲病學分會和肝臟分會. 病毒性肝炎防治方案 . 中華肝臟病雜志, 2000, 8(6): 324-329.
5.	Juni P, Altman DG, Eger M. Assessing the quality of controlled clinical trails. BMJ, 2001, 323: 42-46.
6.	Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.
7.	Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11): 1539-1558.
8.	江堤, 揚光, 羅萬蓉. 阿德福韋聯合苦參素治療HBeAg 陰性慢性乙肝效果研究. 現代預防醫學, 2009, 36(8): 1587-1590.
9.	姬憲立, 姬瑞英, 張佰健. 阿德福韋脂聯合苦參素治療慢性乙型肝炎的療效觀察. 中國實用醫藥, 2006, 1(1): 2-3.
10.	顏晶曉. 阿德福韋酯合苦參素膠囊治療慢性乙型肝炎. 浙江中西醫結合雜志, 2008, 18(3): 172-173.
11.	陸寧, 徐園. 阿德福韋酯聯合苦參素治療YMDD 變異慢性乙型肝炎患者的療效. 中國醫院藥學雜志, 2008, 28(17): 1484-1486.
12.	呂開雪. 阿德福韋酯聯合苦參素治療拉米夫定耐藥慢性乙肝的研究. 現代醫藥衛生, 2007, 23(20): 3011-3012.
13.	韋健盛, 張玲. 阿德福韋酯聯合苦參素治療慢性乙型肝炎33例. 實用中醫內科雜志, 2008, 22(3): 38-40.
14.	李春玉, 張學武. 阿德福韋酯聯合苦參素治療慢性乙型肝炎的臨床研究. 實用肝臟病雜志, 2008, 11(6): 370-372.
15.	趙端壁. 阿德福韋酯與苦參素聯合治療HBeAg 陽性慢性乙型肝炎的療效觀察. 實用醫學雜志, 2008, 24(1): 117-118.
16.	劉興峰. 苦參素膠囊聯合阿德福韋酯治療慢性乙型肝炎的臨床研究. 河北醫學, 2006, 13(3): 256-258.
17.	陳巖. 苦參素聯合阿德福韋酯治療慢性乙型肝炎122例. 黑龍江醫藥, 2008, 21(1): 74-76.

1. Liaw Y F, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18(3): 239-245.
2. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to Lamivudine. Hepatolopy, 1998, 27(6): 6701.
3. 楊詩杰. 苦參素聯合拉米夫定對慢性乙型肝炎血清HBsAg影響的Meta 分析. 實用醫學雜志, 2008, 24(13): 2220-2223.
4. 中華醫學會傳染病與寄生蟲病學分會和肝臟分會. 病毒性肝炎防治方案 . 中華肝臟病雜志, 2000, 8(6): 324-329.
5. Juni P, Altman DG, Eger M. Assessing the quality of controlled clinical trails. BMJ, 2001, 323: 42-46.
6. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.
7. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11): 1539-1558.
8. 江堤, 揚光, 羅萬蓉. 阿德福韋聯合苦參素治療HBeAg 陰性慢性乙肝效果研究. 現代預防醫學, 2009, 36(8): 1587-1590.
9. 姬憲立, 姬瑞英, 張佰健. 阿德福韋脂聯合苦參素治療慢性乙型肝炎的療效觀察. 中國實用醫藥, 2006, 1(1): 2-3.
10. 顏晶曉. 阿德福韋酯合苦參素膠囊治療慢性乙型肝炎. 浙江中西醫結合雜志, 2008, 18(3): 172-173.
11. 陸寧, 徐園. 阿德福韋酯聯合苦參素治療YMDD 變異慢性乙型肝炎患者的療效. 中國醫院藥學雜志, 2008, 28(17): 1484-1486.
12. 呂開雪. 阿德福韋酯聯合苦參素治療拉米夫定耐藥慢性乙肝的研究. 現代醫藥衛生, 2007, 23(20): 3011-3012.
13. 韋健盛, 張玲. 阿德福韋酯聯合苦參素治療慢性乙型肝炎33例. 實用中醫內科雜志, 2008, 22(3): 38-40.
14. 李春玉, 張學武. 阿德福韋酯聯合苦參素治療慢性乙型肝炎的臨床研究. 實用肝臟病雜志, 2008, 11(6): 370-372.
15. 趙端壁. 阿德福韋酯與苦參素聯合治療HBeAg 陽性慢性乙型肝炎的療效觀察. 實用醫學雜志, 2008, 24(1): 117-118.
16. 劉興峰. 苦參素膠囊聯合阿德福韋酯治療慢性乙型肝炎的臨床研究. 河北醫學, 2006, 13(3): 256-258.
17. 陳巖. 苦參素聯合阿德福韋酯治療慢性乙型肝炎122例. 黑龍江醫藥, 2008, 21(1): 74-76.

Previous Article
Asarone Injection in Treating Respiratory Disease: A Meta-analysis
Next Article
Bisphosphonates for Multiple Myeloma: A Systematic Review

Chinese Journal of Evidence-Based Medicine

Efficacy and Safety of Kushenin combined with Adefovir Dipivoxil in the Treatment of Chronic Hepatitis B: A Systematic Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content